SUBSCRIBE
SUBSCRIBE
News   Drug Development

Neurocrine Biosciences, Inc., GlaxoSmithKline Depression Drug GSK561679 Fails Mid-Stage Trial

September 15, 2010 | 
1 min read
LOS ANGELES, Sept 14 (Reuters) - Neurocrine Biosciences Inc (NBIX.O) said an experimental depression drug it was developing with GlaxoSmithKline PLC (GSK.L) failed in a mid-stage trial to work better than a dummy drug.
Clinical research Phase II
GlaxoSmithKline
MORE ON THIS TOPIC
IN PARTNERSHIP WITH IQVIA
AI Is Taking Over Drug Safety Monitoring–But There’s One Thing It Can’t Replace
July 17, 2025
 · 
1 min read
 · 
Lori Ellis
Exclusive magazine sketch collage image of happy businesswoman businessman stand question mark strategy ceo magnifier search job.
Neuropsychiatric disorders
Otsuka, Lundbeck’s PTSD Bid for Rexulti Hits Speedbump as FDA Questions Efficacy
July 17, 2025
 · 
2 min read
 · 
Tristan Manalac
IN PARTNERSHIP WITH EVOTEC
Webinar: Pharma Industry in Crisis
July 16, 2025
 · 
1 min read
 · 
BioSpace Insights
Goal disorientation and lack of vision. Inability to set the right business objectives. Failure to achieve the objectives. Missing the unrealistic and inaccurate company goals.
Rare diseases
AstraZeneca’s Amyloidosis Asset Stumbles in Late-Stage Trials
July 16, 2025
 · 
1 min read
 · 
Dan Samorodnitsky